MoonLake Immunotherapeutics

Stories

MoonLake's Nanobody drug clears its second Phase 3 test

As of August 2026: Advancing sonelokimab toward its first filings

MoonLake's experimental drug sonelokimab hit its main goal in a second late-stage trial, this time in psoriatic arthritis. The win moves the small Swiss biotech's Nanobody drug closer to two separate markets.

Updated Aug 10

MoonLake pushes sonelokimab toward FDA approval for a painful skin disease

New Capabilities

As of June 2026: Targeting BLA submission by end-September 2026; proposed $150 million equity offering on June 22 to fund commercialization

Hidradenitis suppurativa causes painful, recurring abscesses in the skin folds of an estimated 2 in 100 people, by MoonLake's count. For most of the past decade, one drug controlled it well enough to win U.S. approval.

Updated Jun 23